¿Me estás escuchando? : cómo conversar con niños entre los 4 y los 12 años

Resumen basado en el de la publicaciónSe aborda cómo mantener conversaciones con niños de cuatro a doce años, describiendo y analizando las conversaciones en general y orientando en su realización. Se muestra una especial atención a las charlas asistenciales y al medio escolar. Se integran los resultados de otras investigaciones al respecto y se ofrece un modelo conversacional según la edad.MadridBiblioteca de Educación del Ministerio de Educación, Cultura y Deporte; Calle San Agustín 5 -3 Planta; 28014 Madrid; Tel. +34917748000; [email protected]

Analysis of Adaptive Dynamical Systems for Eating Regulation Disorders

To analyse a subject's mental processes, psychotherapists often face nontrivial properties of adaptive dynamical systems

Modelling Adaptive Dynamical Systems to analyse Eating Regulation Disorders. Simulation Journal: Transactions of the Society for Modeling and Simulation

Abstract. To analyse the disorders of their patients, psychotherapists often have to get insight in adaptive dynamical systems. Analysis of dynamical systems usually is performed using mathematical techniques. Such an analysis is not precisely the type of reasoning performed in psychotherapy practice. In this paper it is shown how practical reasoning about dynamic properties of adaptive dynamical systems within psychotherapy can be described using a high-level logical language to describe dynamics. Using this language, an executable model has been developed of the dynamics of eating regulation disorders. Based on this model, a number of simulation traces have been generated, both for wellfunctioning situations and for different types of malfunctioning situations that correspond to the first phase of well-known disorders such as anorexia (nervosa), obesitas, and bulimia. Next, it is shown how such traces can be automatically analysed against a number of dynamic properties. 1

Modeling adaptive dynamical systems to analyze eating regulation disorders

Contains fulltext : 55627.pdf (publisher's version ) (Closed access)To analyze the disorders of their patients, psychotherapists often have to get insight in adaptive dynamical systems. Analysis of dynamical systems usually is performed using mathematical techniques. Such an analysis is not precisely the type of reasoning performed in psychotherapy practice. In this article, it is shown how practical reasoning about dynamic properties of adaptive dynamical systems within psychotherapy can be described using a high-level logical language to describe dynamics. Using this language, an executable model has been developed of the dynamics of eating regulation disorders. Based on this model, a number of simulation traces have been generated, both for well-functioning situations and for different types of malfunctioning situations that correspond to the first phase of well-known disorders such as anorexia (nervosa), obesitas, and bulimia. Next, it is shown how such traces can be automatically analyzed against a number of dynamic properties

Prevalence of Autism Spectrum Disorders in Ecuador: A Pilot Study in Quito

This research presents the results of the first phase of the study on the prevalence of pupils with Autism Spectrum Disorder (ASD) in regular education in Quito, Ecuador. One-hundred-and-sixty-one regular schools in Quito were selected with a total of 51,453 pupils. Prevalence of ASD was assessed by an interview with the rector of the school or its delegate. Results show an extremely low prevalence of 0.11 % of pupils with any ASD diagnosis; another 0.21 % were suspected to have ASD, but were without a diagnosis. This low prevalence suggests that children and adolescents with ASD are not included in regular education in Quito. These results are discussed in the light of low diagnostic identification of ASD and low inclusion tolerance

Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry

Background: COVID-19 has been associated with a broad range of thromboembolic, ischemic, and hemorrhagic complications (coagulopathy complications). Most studies have focused on patients with severe disease from high-income countries (HICs). Objectives: The main aims were to compare the frequency of coagulopathy complications in developing countries (low- and middle-income countries [LMICs]) with those in HICs, delineate the frequency across a range of treatment levels, and determine associations with in-hospital mortality. Methods: Adult patients enrolled in an observational, multinational registry, the International Severe Acute Respiratory and Emerging Infections COVID-19 study, between January 1, 2020, and September 15, 2021, met inclusion criteria, including admission to a hospital for laboratory-confirmed, acute COVID-19 and data on complications and survival. The advanced-treatment cohort received care, such as admission to the intensive care unit, mechanical ventilation, or inotropes or vasopressors; the basic-treatment cohort did not receive any of these interventions. Results: The study population included 495,682 patients from 52 countries, with 63% from LMICs and 85% in the basic treatment cohort. The frequency of coagulopathy complications was higher in HICs (0.76%-3.4%) than in LMICs (0.09%-1.22%). Complications were more frequent in the advanced-treatment cohort than in the basic-treatment cohort. Coagulopathy complications were associated with increased in-hospital mortality (odds ratio, 1.58; 95% CI, 1.52-1.64). The increased mortality associated with these complications was higher in LMICs (58.5%) than in HICs (35.4%). After controlling for coagulopathy complications, treatment intensity, and multiple other factors, the mortality was higher among patients in LMICs than among patients in HICs (odds ratio, 1.45; 95% CI, 1.39-1.51). Conclusion: In a large, international registry of patients hospitalized for COVID-19, coagulopathy complications were more frequent in HICs than in LMICs (developing countries). Increased mortality associated with coagulopathy complications was of a greater magnitude among patients in LMICs. Additional research is needed regarding timely diagnosis of and intervention for coagulation derangements associated with COVID-19, particularly for limited-resource settings

Implementation of Recommendations on the Use of Corticosteroids in Severe COVID-19

Importance: Research diversity and representativeness are paramount in building trust, generating valid biomedical knowledge, and possibly in implementing clinical guidelines. Objectives: To compare variations over time and across World Health Organization (WHO) geographic regions of corticosteroid use for treatment of severe COVID-19; secondary objectives were to evaluate the association between the timing of publication of the RECOVERY (Randomised Evaluation of COVID-19 Therapy) trial (June 2020) and the WHO guidelines for corticosteroids (September 2020) and the temporal trends observed in corticosteroid use by region and to describe the geographic distribution of the recruitment in clinical trials that informed the WHO recommendation. Design, setting, and participants: This prospective cohort study of 434 851 patients was conducted between January 31, 2020, and September 2, 2022, in 63 countries worldwide. The data were collected under the auspices of the International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC)-WHO Clinical Characterisation Protocol for Severe Emerging Infections. Analyses were restricted to patients hospitalized for severe COVID-19 (a subset of the ISARIC data set). Exposure: Corticosteroid use as reported to the ISARIC-WHO Clinical Characterisation Protocol for Severe Emerging Infections. Main outcomes and measures: Number and percentage of patients hospitalized with severe COVID-19 who received corticosteroids by time period and by WHO geographic region. Results: Among 434 851 patients with confirmed severe or critical COVID-19 for whom receipt of corticosteroids could be ascertained (median [IQR] age, 61.0 [48.0-74.0] years; 53.0% male), 174 307 (40.1%) received corticosteroids during the study period. Of the participants in clinical trials that informed the guideline, 91.6% were recruited from the United Kingdom. In all regions, corticosteroid use for severe COVID-19 increased, but this increase corresponded to the timing of the RECOVERY trial (time-interruption coefficient 1.0 [95% CI, 0.9-1.2]) and WHO guideline (time-interruption coefficient 1.9 [95% CI, 1.7-2.0]) publications only in Europe. At the end of the study period, corticosteroid use for treatment of severe COVID-19 was highest in the Americas (5421 of 6095 [88.9%]; 95% CI, 87.7-90.2) and lowest in Africa (31 588 of 185 191 [17.1%]; 95% CI, 16.8-17.3). Conclusions and relevance: The results of this cohort study showed that implementation of the guidelines for use of corticosteroids in the treatment of severe COVID-19 varied geographically. Uptake of corticosteroid treatment was lower in regions with limited clinical trial involvement. Improving research diversity and representativeness may facilitate timely knowledge uptake and guideline implementation